Abbvie Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
All right. Thank you for joining us, everyone. I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets, and I'm pleased to be joined by AbbVie for our next presentation.
Joining us this afternoon are Mike Severino, Vice Chairman and President; Rob Michael, Executive Vice President and CFO; Jeff Stewart, Executive Vice President of Commercial Operations; and Liz Shea, Head of IR. So thank you all for being here.
There's a lot to talk about. And given the limited time we have, I think it makes sense to jump right into Q&A.
Questions & Answers
So maybe to begin with the immunology business. I'd like to talk a little bit about Humira, SKYRIZI and RINVOQ, obviously, a lot going on. Humira and SKYRIZI already blockbuster products, RINVOQ is well on its way. Late last year, you provided combined 0.25 risk-adjusted sales guidance for SKYRIZI and RINVOQ of greater than $15 billion.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
